Table 2.
Enrichment of gene mutations in specific clinical features
| Gene alteration | RASa | BRAF | TERT promoter |
|---|---|---|---|
| Histological variant | FVPTC |
CVPTC TCPTC |
– |
| Lymph node status | pN0 | pN1a | – |
| Extrathyroidal extension | – | Minimal | Gross |
| Distant metastasis | – | – | pM1 |
| Age | – | – |
>45 years >55 years |
| ATA risk | Low | Intermediate | High |
| AJCC 7th edition | – | – | Stage IV |
| AJCC 8th edition | – | – | Stages II, III, IV |
| Persistence of disease | – | – | Yes |
| Death | – | – | Yes |
Only significant results are showed
aFor histological variant, it refers to HRAS and NRAS; for the other features, it refers to NRAS only
FVPTC Follicular Variant of Papillary Thyroid Carcinoma, CVPTC Classical Variant of Papillary Thyroid Carcinoma, TCPTC Tall Cell Variant of Papillary Thyroid Carcinoma, ATA American Thyroid Association, AJCC American Joint Committee on Cancer